[前列腺癌的新生物标志物]
[The new biomarkers of prostate cancer].
作者信息
Bessede T, Malavaud B
机构信息
Service d'Urologie, Hôpital Bicêtre, 78, rue du Général Leclerc, 94275 Le Kremlin-Bicêtre Cedex, France.
出版信息
Prog Urol. 2011 Mar;21 Suppl 2:S63-7. doi: 10.1016/S1166-7087(11)70014-8.
Biomarkers of prostate cancer can assess a presence risk or an evolution risk of the disease. The integration of temporal and clinical data during the interpretation of a PSA dosage improves its performance. Trough a performing algorithm, the Phi index (Prostate Health Index) combines the results of total PSA, free PSA, and pro-PSA. The ration of urinary PCA3 and urinary PSA determines a powerful marker to be used in difficult diagnostic situations. Gene fusions in prostate cancer are promising biomarkers and eventual therapeutic targets. The cost of these new biomarkers is limiting their current use to individual situations.
前列腺癌生物标志物可评估该疾病的患病风险或病情进展风险。在解读前列腺特异抗原（PSA）检测结果时整合时间和临床数据可提高其性能。通过一种有效的算法，Phi指数（前列腺健康指数）综合了总PSA、游离PSA和前列腺特异性抗原（pro-PSA）的检测结果。尿PCA3与尿PSA的比值是一种在疑难诊断情况下可用的强大标志物。前列腺癌中的基因融合是很有前景的生物标志物及潜在治疗靶点。这些新型生物标志物的成本限制了它们目前仅用于个别情况。
Zotero 插件